NCT02116972View on ClinicalTrials.gov

Study of FX006 vs Normal Saline in Patients With Osteoarthritis of the Knee

PHASE2CompletedINTERVENTIONAL
Enrollment

310

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions
Osteoarthritis of the Knee
Interventions
DRUG

FX006 32 mg

Single 5 mL IA injection

DRUG

Placebo

Single 5 mL IA injection

DRUG

FX006 16 mg

Single 5 mL IA injection

Trial Locations (44)

10018

New York

14609

Rochester

16602

Altoona

16635

Duncansville

20902

Wheaton

24541

Danville

27612

Raleigh

29464

Mt. Pleasant

30060

Marietta

32720

DeLand

32825

Orlando

33316

Fort Lauderdale

33613

Tampa

33781

Pinellas Park

35216

Birmingham

36207

Anniston

36608

Mobile

42003

Paducah

47713

Evansville

48085

Troy

64114

Kansas City

71913

Hot Springs

73112

Oklahoma City

75231

Dallas

77055

Houston

77901

Victoria

78258

San Antonio

85023

Phoenix

85704

Tucson

87102

Albuquerque

89106

Las Vegas

90036

Los Angeles

91303

Canoga Park

91606

North Hollywood

92020

El Cajon

92103

San Diego

92801

Anaheim

06905

Stamford

02740

New Bedford

Unknown

Kitchener

Sarnia

Toronto

Windsor

Québec

Sponsors
All Listed Sponsors
lead

Pacira Pharmaceuticals, Inc

INDUSTRY

NCT02116972 - Study of FX006 vs Normal Saline in Patients With Osteoarthritis of the Knee | Biotech Hunter | Biotech Hunter